McKesson Q4 Earnings Call Highlights
McKesson (NYSE:MCK) reported a stronger fiscal fourth quarter and full fiscal 2026 performance, with executives pointing to growth across its oncology, multispecialty, pharmaceutical distribution and prescription technology businesses, while outlining plans for continued earnings growth in fiscal 20
MarketBeat ·